PubMed Health⌕ Search

Biomedical subjects

M Bergbauer

Publications and source records attributed to M Bergbauer.

10 recordsLinked to original sources
PubMed1989

[A transdermal intermittent-release nitroglycerin system. Hemodynamic studies after acute and subchronic use].

The efficacy of a transdermal intermittent-release nitroglycerin system was investigated in a randomized double-blind trial on 24 patients (18 males and six females; median age 57.5 years [range 41-68]) with angiographically proven and haemodynamically significant coronary heart disease. Twelve patients had one plaster, containing 10 mg nitroglycerin, daily for eight days, the other twelve also had one plaster, but without drug, daily for eight days. Resting and exercise haemodynamics were measured on the first day, immediately before and two hours after application of the plaster, on the eighth day 24 hours after the last but one plaster application, and two hours after the last plaster. The mean pulmonary artery pressure, two hours after first plaster application, had dropped at rest from 18.6 to 13.3 mm Hg (29%; P less than 0.001) and after exercise from 43.9 to 34 mm Hg (23%; P less than 0.001). After eight days, 24 hours after application of the penultimate plaster, there was no significant haemodynamic change. Renewed plaster application, however, caused significant haemodynamic changes similar to those on the first day of the study. It is concluded from these findings that this intermittent-release system can achieve long-term results without development of tolerance.

Administration, Cutaneous↗
PubMed1989

Haemodynamic studies with a phasic release nitroglycerin patch system.

The use of transdermal nitroglycerin (GTN) patches in patients with coronary artery disease is of uncertain value as numerous investigators have failed to confirm clinical efficacy for more than 8h. This relatively short duration of action is an indication of rapidly developing tolerance due to the relatively constant GTN plasma levels following GTN patch application. We investigated the efficacy of a newly developed GTN patch with a discontinuous release profile in 28 patients with coronary heart disease. Two hours after initial administration, pulmonary capillary wedge (PCW) pressure decreased by 25.7% at rest and by 25.1% during exercise. Cardiac index at rest decreased by 12.2%. No significant changes were observed in systemic blood pressure and heart rate. No significant haemodynamic effects were apparent after 24h. Following renewed GTN patch application, a decrease in PCW pressure occurred, similar to that observed after acute administration. After 1 week of daily therapy, similar changes were observed: 24h after patch application, PCW was similar to baseline values but showed a significant decrease 2h after patch re-application. These data suggest that the phasic release GTN patch is not associated with tolerance to the haemodynamic effects during sustained once daily therapy.

Administration, Cutaneous↗
PubMed1989

Left ventricular after load as a result of levocardiography with contrast media of various osmolality.

Contrast media have been successfully used as a diagnostic aid in radiology for decades. It has, however, been necessary to accept certain, in some cases unexplained, undesirable side effects because of their physicochemical properties. The conventional preparations available have for more than 40 years been iodinated salts or acids, whose major disadvantage has been high osmolality. For some years now, a new generation of contrast media has been available. These contrast media exhibit a far lower osmolality due to the lack of ionicity. As a result of the volume load of the left ventricle by levocardiography, there is usually an increase of the left ventricular end-diastolic pressure in the pathologic range over 12 mmHg. We were able to prove this in 120 consecutive patients whom we examined. The pressure increase with the use of nonionic contrast media was considerably lower. The differentiated observation of various risk groups showed no signs of valid predictive parameters.

Cardiac Output↗
PubMed1986

Inhibitory effect of nifedipine on cholecystokinin-induced gallbladder contraction in man.

A prospective study was performed on seven male and eight female patients with normal hepatobiliary findings to investigate the effect of 20 mg nifedipine on cholecystokinin-induced gallbladder contraction. Each patient received 1 IDU (Ivy dog unit) cholecystokinin per kg body weight intravenously on two consecutive days, with additional administration of 20 mg nifedipine sublingually on the second day. Gallbladder volumes were assessed by ultrasonography over a period of 25 minutes. Cholecystokinin induced a maximal reduction in the mean initial volume of 56.8 +/- 3.6%. After nifedipine, this volume change was significantly reduced to 30.9 +/- 5.1% (p less than 0.001). Thus our data suggest for the first time that the calcium-channel-blocking agent nifedipine can have an effect on human gallbladder kinetics.

Adult↗
PubMed1985

DNA methyltransferase genes of Bacillus subtilis phages: structural relatedness and gene expression.

The DNA methyltransferase (Mtase) genes of temperate Bacillus subtilis phages phi 3T, rho 11 and SP beta were cloned and expressed in Escherichia coli. Each gene specifies a 47-kDa1 protein, which modifies BsuR (GGCC) and Fnu4HI (GCNGC) target sequences. Transcription is controlled by phage promoters located on the cloned fragments. The direction of transcription and the approximate position of the Mtase genes were determined. DNA/DNA hybridization experiments revealed close structural relatedness of the phi 3T, rho 11 and SP beta genes. A significant degree of homology was also found among these genes and the Mtase gene of related phage SPR, which codes for an enzyme with different modification specificity. These results suggest a common ancestor of the different phage Mtase genes. Phage Z, the only BsuR-sensitive member of this phage group, lacks a modification gene, but contains regions homologous to sequences flanking the SPR, phi 3T, rho 11 and SP beta Mtase genes.

Bacillus subtilis↗